- Home
- CLDI vs RNXT Comparison
CLDI vs RNXT Comparison
Compare CLDI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- RNXT
- Stock Information
- Founded
- CLDI 2014
- RNXT 2012
- Country
- CLDI United States
- RNXT United States
- Employees
- CLDI N/A
- RNXT N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- RNXT Health Care
- Exchange
- CLDI Nasdaq
- RNXT Nasdaq
- Market Cap
- CLDI 18.1M
- RNXT 21.6M
- IPO Year
- CLDI N/A
- RNXT 2021
- Fundamental
- Price
- CLDI $2.16
- RNXT $1.21
- Analyst Decision
- CLDI Strong Buy
- RNXT Strong Buy
- Analyst Count
- CLDI 3
- RNXT 2
- Target Price
- CLDI $16.67
- RNXT $6.13
- AVG Volume (30 Days)
- CLDI 3.5M
- RNXT 42.6K
- Earning Date
- CLDI 11-12-2024
- RNXT 11-13-2024
- Dividend Yield
- CLDI N/A
- RNXT N/A
- EPS Growth
- CLDI N/A
- RNXT N/A
- EPS
- CLDI N/A
- RNXT N/A
- Revenue
- CLDI N/A
- RNXT N/A
- Revenue This Year
- CLDI N/A
- RNXT N/A
- Revenue Next Year
- CLDI N/A
- RNXT N/A
- P/E Ratio
- CLDI N/A
- RNXT N/A
- Revenue Growth
- CLDI N/A
- RNXT N/A
- 52 Week Low
- CLDI $0.73
- RNXT $0.53
- 52 Week High
- CLDI $26.30
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- CLDI 57.07
- RNXT 68.06
- Support Level
- CLDI $2.10
- RNXT $1.04
- Resistance Level
- CLDI $2.51
- RNXT $1.18
- Average True Range (ATR)
- CLDI 0.43
- RNXT 0.10
- MACD
- CLDI 0.04
- RNXT 0.01
- Stochastic Oscillator
- CLDI 36.86
- RNXT 78.61
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.